ERBB2 and breast cancer: The Trastuzumab epitope was also conjugated with doxorubicin, showing a higher anticancer activity, compared to free doxorubicin, not only in vitro in HER-2-positive breast cancer cells (SK-BR3 cells) but also in vivo in xenograft tumors developed in mice [97].